By David Rubert, PhD. Insights from Prof. Dr. Hugues Abriel (Institute of Biochemistry and Molecular Medicine, University of Bern)
This second part of the blog post covers the last part of the conversion with Prof. Hugues Abriel.
The Genomic Diversity Imperative
Africa harbors the greatest human genetic diversity on Earth. Sequencing efforts consistently reveal variants absent in European and Asian datasets. This diversity has profound implications for both disease research and therapeutic development.
At Cheikh Anta Diop University in Dakar, teams are building reference genomes for Senegal’s diverse ethnic groups, each with distinct genetic architectures. The African Society of Human Genetics (AfSHG) has become a key hub for knowledge exchange, while Africa CDC has launched continental initiatives for genomic medicine and pathogen surveillance.
“The reference genome most clinicians use today is essentially European,” says Abriel. “For African patients, this can lead to misinterpretation of variants, misdiagnosis, or exclusion from therapeutic eligibility. Generating African reference genomes is not just a scientific exercise—it is a prerequisite for equity in healthcare.”
Evolutionary Context and Global Health Relevance
The significance of this work extends beyond Africa. The sickle cell trait remains one of the most studied examples of evolutionary medicine: a single nucleotide variant in the HBB gene that, in heterozygotes, confers resistance to malaria. This phenomenon, known as balanced polymorphism, has preserved the variant at high frequency in malaria-endemic regions, even though it causes severe disease in homozygotes.
Such interactions between environment, selection, and genomic variation illustrate why population-specific data are essential for precision medicine. They also highlight the stakes for global health.
Climate change is magnifying these lessons. Southern Europe has already seen outbreaks of arboviruses such as West Nile virus, along with sporadic reappearances of autochthonous malaria. Historical records confirm that malaria was once endemic in the Po Valley of Italy, only eradicated in the mid-20th century through drainage and vector-control campaigns. With shifting ecologies, renewed vulnerability cannot be ruled out.
African genomic initiatives, therefore, are not isolated to one continent. They serve as regional strategies with global relevance, demonstrating how genomic surveillance, portable sequencing, and equitable partnerships can prepare health systems for diseases shaped by evolutionary pressures and environmental change.
Ethical Partnerships: Rejecting “Helicopter Science”
One of Abriel’s strongest messages concerns the ethics of collaboration. Too often, foreign researchers conduct “helicopter science”: collecting samples in Africa, sequencing them abroad, and publishing without meaningful local engagement.
“The worst outcome is to repeat colonial patterns,” he warns. “Real progress comes when projects are co-created with African scientists, when students are trained locally, and when sequencing capacity is built within African institutions.”
In both Dakar and Kinshasa, local scientists led experimental workflows, ensuring knowledge transfer and long-term sustainability. Partnerships with the University of Kinshasa, Cheikh Anta Diop University, and the broader African genomics community ensure that expertise remains embedded in the continent.
The Road Ahead: Overcoming Barriers
Despite promising proof-of-concept results, challenges remain:
- Cold chain logistics. Reagents requiring 4°C or -20°C storage remain vulnerable to delays and customs restrictions.
- Scalability. Expanding coverage in countries as large as the DRC (with 100 million inhabitants and a territory the size of Western Europe) demands networks of mobile labs, not isolated demonstrations.
- Data integration. Generating African genomic data must be coupled with robust local bioinformatics pipelines, data sovereignty frameworks, and clinical integration.
Solutions are emerging. Lyophilized reagents, solar-powered freezers, and cloud-based bioinformatics platforms offer partial answers. The next frontier is institutional scaling: moving from pilot projects to continent-wide deployment under the leadership of Africa CDC and African universities.
Rewriting the Geography of Medicine
The experiments in Dakar and Kinshasa represent more than a technical achievement. They are a reimagining of how genomics can be conducted: portable, collaborative, and equitable. By bridging the gap between European institutions (University of Bern, German collaborators, Xpedite Diagnostics) and African leaders (University of Kinshasa, Cheikh Anta Diop University, AfSHG, Africa CDC), the project sets a model for future partnerships.
Prof. Abriel ends “Our objective extends beyond DNA sequencing: it is the development of durable infrastructures, locally embedded expertise, and equitable frameworks to ensure that Africa’s genomic diversity is systematically integrated into global medicine.”